Hyundai Bioscience amends semiannual report to add treasury stock disclosure

• Hyundai Bioscience filed a corrected semi-annual report for the six months ended June 30, 2026.
• Correction added treasury share disclosures, including 2,256 common shares held for fractional-share processing since 2011.
• No short-term plan for treasury share acquisition, disposal, or cancellation was reported for 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hyundai Bioscience Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261002000649), on October 02, 2026, and is solely responsible for the information contained therein.